Leukemias PDX

Patient Derived Xenograft (PDX) Mouse Models and Efficacy Services
Leukemias PDXStomach Cancer PDXPancreatic Cancer PDXOvarian Cancer PDXLung cancer PDXColorectal Cancer PDXBreast Cancer PDXBladder Cancer PDX
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Anti-PD1 Drug-resistant Tumor ModelsIn Vivo Efficacy Studies Using TIGIT Humanized ModelsPDL1 Humanized Mouse ModelPD1 Humanized Mouse ModelsOX40 Humanized Mouse ModelsIn vivo Efficacy Test in LAG3 Humanized Mouse ModelsIn vivo Efficacy Test in GITR Humanized Mouse ModelCTLA4 Humanized Mouse ModelsIn vivo Efficacy Test in CD137 Humanized Models

Acute myelogenous leukemia (AML), which accounts for nearly 70% of adult leukemias, is one of the most challenging leukemias to cure. FLT3 (FMS-like tyrosine kinase 3), also known as Flk2/CD135, is a type III receptor tyrosine kinase (RTK) that is critical for the survival, proliferation, and differentiation of hematopoietic cells. FLT3 gene mutations are a common genetic variant in AML (approximately 30%) and are associated with a poor clinical prognosis and susceptibility to relapse. Consequently, FLT3 inhibitor research is critical for AML treatment. The construction of the AML-PDX model requires additional human cytokines to help AML leukemia cells escape residual innate immune surveillance in mice in a specific supportive stromal cell milieu and subsequently home and expand in mice. GemPharmatech's NCG-M mouse strain outperforms a conventional, severely immunodeficient mouse without human cytokine assistance in terms of modeling efficiency. AML-PDX models with FLT3 mutations have been developed and are suitable for drug sensitivity testing as well as preclinical efficacy evaluation of various AML therapies.


图片1.png

Figure 1. The hCD45+ cells percentage in peripheral blood increased gradually after AML-PDX modeling. The NCG-M mouse strain outperformed the NCG strain in terms of modeling efficiency.

图片2.png

Figure 2. Characteristic markers such as hCD45+, hCD33+, and hCD135+ (FLT3) were identified in the peripheral blood of mice at various stages after the AML-PDX models were passaged. Lower inoculum doses successfully amplified AML-PDX models in the NCG-M strain, and the efficacy and quality of modeling were dose-dependent.





image.png

TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.